Author

Shogen Boku

Observed name: S. Boku

Institution: Kansai Medical University Hospital

Observed institutions: Kansai Medical University, Kansai Medical University Hospital

ORCID: 0000-0002-5015-0379

Observed ORCID: 0000-0002-5015-0379

OpenAlex ID: A5032916779

HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry

2026 · Michiko Nagamine, Takao Fujisawa, et al. · JCO Precision Oncology · 3

1130P Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial

2024 · M. Nomura, M. Yoshimura, et al. · Annals of Oncology · 3

Caffeic acid suppresses cyclin D1 expression by directly binding to ribosomal protein S5 in colorectal cancer cells

2026 · Motoki Watanabe, Shogen Boku, et al. · Scientific Reports · 2

10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC)

2025 · K. Yamaguchi, A. Takashima, et al. · Annals of Oncology · 2

BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

2024 · Y. Matsubara, H. Bando, et al. · ESMO Gastrointestinal Oncology · 2

1711P A phase III study of combination therapy with everolimus plus lanreotide (E/L) versus everolimus monotherapy (E) for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (JCOG1901, STARTER-NET): Updated results and central pathological review (CPR)

2025 · N. Mizuno, S. Hijioka, et al. · Annals of Oncology · 1

Conversion surgery for stage IV gastric cancer: Real-world insights with a focus on elderly patients (OGSG2301).

2026 · Yuichiro Miki, Taroh Satoh, et al. · Journal of Clinical Oncology

Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701).

2026 · Ryohei Kawabata, Yutaka Kimura, et al. · Journal of Clinical Oncology

79P The role of regorafenib for metastatic colorectal cancer in the new era of later-line treatment: Results of the OSERO study

2024 · T. Matsumoto, T. Kawakami, et al. · Annals of Oncology

115P Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer

2024 · T. Shibuki, C. Morizane, et al. · ESMO Open

126P Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study

2022 · K. Shimozaki, K. Sugiyama, et al. · Annals of Oncology

Works count: 11

Citation count: 13

H-index: 2

I10-index: